Mga Batayang Estadistika
| LEI | LEBZ6VLQ6I8XB1NHVY15 |
| CIK | 1109354 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bruker Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Bruker Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offering. |
|
| September 5, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-272381 PROSPECTUS SUPPLEMENT (To Prospectus dated June 2, 2023) 2,400,000 Shares 6.375% Mandatory Convertible Preferred Stock, Series A We are offering 2,400,000 shares of our 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Dividends on the Mand |
|
| September 4, 2025 |
Bruker Corporation 2,400,000 Shares of 6.375% Mandatory Convertible Preferred Stock, Series A Pricing Term Sheet Free Writing Prospectus dated as of September 3, 2025 Filed pursuant to Rule 433 Supplementing the Preliminary Prospectus Supplement dated September 2, 2025 to the Prospectus dated June 2, 2023 Registration No. |
|
| September 2, 2025 |
Subject to Completion, dated September 2, 2025 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUK |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer inc |
|
| August 4, 2025 |
Bruker Reports Second Quarter 2025 Financial Results Exhibit 99.1 Bruker Reports Second Quarter 2025 Financial Results • Q2 2025 revenues of $797.4 million, down 0.4% year-over-year (yoy); organic revenue down 7.0%, and constant-exchange rate (CER) revenue down 3.3% • Q2 2025 GAAP diluted EPS $0.05; non-GAAP diluted EPS $0.32 • Announcing a significantly expanded cost savings initiative expected to reduce annual costs by $100 - $120 million in FY 20 |
|
| July 21, 2025 |
Exhibit 99.1 Bruker Announces Second Quarter 2025 Preliminary Results, Plans to Hold Q2 Earnings Conference Call on August 4, 2025 BILLERICA, Massachusetts— July 21, 2025— Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the second quarter ended June 30, 2025 in a range of $795 - $798 million, which implies approximately flat reported revenue year-over-year. Bruker estimat |
|
| July 21, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer inco |
|
| May 30, 2025 |
Conflict Minerals Report of Bruker Corporation. Exhibit 1.01 Bruker Corporation Conflict Minerals Report For the Reporting Period from January 1, 2024, to December 31, 2024 Introduction This Conflict Minerals Report (“Report”) of Bruker Corporation and its consolidated subsidiaries for the reporting period from January 1, 2024, to December 31, 2024 (“Reporting Period”) has been prepared pursuant to Rule 13p-1 (the “Rule”) promulgated under the |
|
| May 30, 2025 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report BRUKER CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-30833 04-3110160 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 40 Manning Road, Billerica, MA 01821 (Address of principal executive office |
|
| May 29, 2025 |
Bruker Corporation 2026 Incentive Compensation Plan EXHIBIT 10.1 BRUKER CORPORATION 2026 INCENTIVE COMPENSATION PLAN Section 1. Effectiveness and Purpose. Effective as of the Effective Date, the Bruker Corporation 2026 Incentive Compensation Plan (as may be amended from time to time, the “Plan”) is hereby established. The purpose of the Plan is to provide employees of Bruker Corporation, a Delaware corporation (together with its successors, the “Co |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Employ |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 14, 2025 |
Bruker and 10x Genomics Reach Global Settlement of Patent Litigation Bruker and 10x Genomics Reach Global Settlement of Patent Litigation BILLERICA, Massachusetts – May 14, 2025 – Bruker Corporation (Nasdaq: BRKR) today announced that Bruker and 10x Genomics have reached a final settlement to resolve their patent disputes and dismiss multiple litigations, with global patent cross license agreements between the two companies. |
|
| May 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer incor |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRU |
|
| May 7, 2025 |
Bruker Reports First Quarter 2025 Financial Results Exhibit 99.1 Bruker Reports First Quarter 2025 Financial Results • Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% • Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds • Guidance on organic revenue and E |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer incorp |
|
| April 11, 2025 |
UNITED STATES SCHEDULE 14A Bruker Corporation BRUKER CORPORATION BRUKER CORPORATION PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer inc |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 11, 2025 |
Bruker Announces First Quarter 2025 Preliminary Revenue Exhibit 99.1 Bruker Announces First Quarter 2025 Preliminary Revenue BILLERICA, Massachusetts— April 11, 2025— Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025 in a range of $795 million to $800 million, comparing favorably to the Company’s earlier outlook and well ahead of consensus. This estimated range implies reported revenue grow |
|
| March 3, 2025 |
Bruker Corporation Compensation Recoupment Policy EXHIBIT 97.1 BRUKER CORPORATION COMPENSATION RECOUPMENT POLICY 1. Purpose Bruker Corporation (“Bruker” or the “Company”) has adopted this Compensation Recoupment Policy (“Policy”) to implement the mandatory recoupment or “clawback” of compensation in the event of a Restatement in compliance with the applicable rules of the Nasdaq Stock Market (“Nasdaq”). Capitalized terms used, but not immediately |
|
| March 3, 2025 |
EXHIBIT 21.1 SUBSIDIARIES OF BRUKER CORPORATION Name of Subsidiary Jurisdiction of Incorporation Agapetus GmbH Austria Alicona Imaging GmbH Austria Anasys Instruments Corporation California, U.S.A. Berkeley Lights Life Science (Shanghai) Co. Ltd. China Berkeley Lights Life Science (Singapore) Pte. Ltd. Singapore Biognosys, AG Switzerland Biognosys, Inc. Delaware, U.S.A. BLI Europe International, L |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION (Exact |
|
| March 3, 2025 |
Insider Trading Policy of Bruker Corporation. EXHIBIT 19.1 INSIDER TRADING POLICY Table of Contents 1. Introduction 2 2. Application 2 2.1 Post-Termination Application 2 3. Bruker Policy 2 4. Unauthorized Disclosure 3 5. Blackouts and Pre-Clearances During Open Trading Windows 3 5.1 Quarterly Blackout Period 3 5.2 Event-Specific Trading Restrictions (Special Blackout Periods) 3 5.3 Pre-Clearance of Trades by Directors, Officers, and Key Perso |
|
| February 21, 2025 |
Bruker Appoints Laura Francis to its Board of Directors Exhibit 99.1 Bruker Appoints Laura Francis to its Board of Directors BILLERICA, Massachusetts - February 21, 2025 – Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker’s Audit Committee as a financial expert after Bru |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer |
|
| February 13, 2025 |
Bruker Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Bruker Reports Fourth Quarter and Full Year 2024 Financial Results • Q4 2024 revenues of $979.6 million, up 14.6% year-over-year (yoy); Bruker organic revenue up 3.9%, and constant-exchange rate (CER) revenue up 15.8%; Bruker Scientific Instrument (BSI) segment organic revenue up 4.5% • Q4 2024 non-GAAP operating margin of 18.1%, as operational excellence and integration initiatives f |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer i |
|
| January 13, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer i |
|
| November 13, 2024 |
BRKR / Bruker Corporation / Polar Capital Holdings Plc Passive Investment SC 13G/A 1 polar-brkr093024a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* BRUKER CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 116794108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 12, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* BRUKER CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 116794108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 |
|
| November 5, 2024 |
Bruker Reports Third Quarter 2024 Financial Results Exhibit 99.1 Bruker Reports Third Quarter 2024 Financial Results • Q3 2024 revenues of $864.4 million, up 16.4% year-over-year (yoy); Bruker organic revenue up 3.1% yoy, and CER revenue up 15.7% yoy; BSI segment organic revenue up 3.8% yoy • Q3 2024 GAAP diluted EPS $0.27; non-GAAP diluted EPS $0.60 • Updated FY2024 guidance: o Revenue $3.34 to $3.37 billion, implying Bruker organic revenue growth |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer i |
|
| August 9, 2024 |
EXHIBIT 10.3 April 11, 2024 To: Purchasers named in the Purchaser Schedule to the Note Purchase Agreement described below Re: CHF 50,000,000 Series A Senior Notes due 2036 CHF 50,000,000 Series B Senior Notes due 2039 of Bruker Corporation Ladies and Gentlemen: Reference is hereby made to the Note Purchase Agreement dated as of February 8, 2024 (the “Note Purchase Agreement”), entered into by the |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUK |
|
| August 9, 2024 |
EXHIBIT 10.2 April 11, 2024 To: Purchasers named in the Purchaser Schedule to the Note Purchase Agreement described below Re: CHF 50,000,000 Series A Senior Notes due 2034 CHF 146,000,000 Series B Senior Notes due 2036 CHF 135,000,000 Series C Senior Notes due 2039 of Bruker Corporation Ladies and Gentlemen: Reference is hereby made to the Note Purchase Agreement dated as of February 1, 2024 (the |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-30833 04-3110160 (State or other jurisdiction of incorporation) (Commission File |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer inc |
|
| August 6, 2024 |
Bruker Reports Second Quarter 2024 Financial Results Exhibit 99.1 Bruker Reports Second Quarter 2024 Financial Results • Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy • Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy • Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and orga |
|
| June 5, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-30833 04-3110160 (State or other jurisdiction of incorporation) (Commission File |
|
| May 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Bruker Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0. |
|
| May 31, 2024 |
Exhibit 99.1 Bruker Announces Public Offering of Common Stock May 29, 2024 BILLERICA, Mass.-(BUSINESS WIRE)- Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 share |
|
| May 31, 2024 |
Exhibit 1.1 BRUKER CORPORATION (a Delaware corporation) 6,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: May 29, 2024 BRUKER CORPORATION (a Delaware corporation) 6,000,000 Shares of Common Stock UNDERWRITING AGREEMENT May 29, 2024 BofA Securities, Inc. J.P. Morgan Securities LLC c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o J.P Morgan Securities LLC 383 Madis |
|
| May 31, 2024 |
Financial Statements and Exhibits, Other Events, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-30833 04-3110160 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 31, 2024 |
6,000,000 Shares Bruker Corporation COMMON STOCK TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-279783 PROSPECTUS 6,000,000 Shares Bruker Corporation COMMON STOCK We are offering 6,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “BRKR.” On May 29, 2024 the last reported sale price of our common stock on Nasdaq was $72.55 per share. The underw |
|
| May 31, 2024 |
Bruker Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Bruker Announces Pricing of Public Offering of Common Stock May 29, 2024 BILLERICA, Mass.-(BUSINESS WIRE)—Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the pricing of its previously announced underwritten registered public offering of 6,000,000 shares of its common stock. Additionally, the Company has granted the underwriters a 30-day option to purchase |
|
| May 30, 2024 |
Amended and Restated Bylaws of Bruker Corporation Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF BRUKER CORPORATION (A Delaware Corporation) Table of Contents Page ARTICLE 1 CERTIFICATE OF INCORPORATION 1 Section 1.1 Contents 1 Section 1.2 Certificate in Effect 1 ARTICLE 2 MEETINGS OF STOCKHOLDERS 1 Section 2.1 Place of Meetings; Meetings by Remote Communications 1 Section 2.2 Annual Meeting 2 Section 2.3 Notice of Stockholder Business. 2 Section 2. |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Employ |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Bruker Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0. |
|
| May 24, 2024 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report BRUKER CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-30833 04-3110160 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 40 Manning Road, Billerica, MA 01821 (Address of principal executive office |
|
| May 24, 2024 |
Conflict Minerals Report of Bruker Corporation. Exhibit 1.01 Bruker Corporation Conflict Minerals Report For the Reporting Period from January 1, 2023 to December 31, 2023 Introduction This Conflict Minerals Report (“Report”) of Bruker Corporation and its consolidated subsidiaries for the reporting period from January 1, 2023, to December 31, 2023 (“Reporting Period”) has been prepared pursuant to Rule 13p-1 (the “Rule”) promulgated under the S |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER |
|
| May 2, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer incor |
|
| May 2, 2024 |
Bruker Reports First Quarter 2024 Financial Results Exhibit 99.1 Bruker Reports First Quarter 2024 Financial Results • Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenue up 5.5% yoy • Q1 2024 GAAP EPS of $0.35; non-GAAP EPS of $0.53 • Updated FY 2024 guidance: • Revenue $3.29 to $3.35 billion, up $60 million from prior guidance, implying reported growth of 11% to 1 |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer incorp |
|
| May 2, 2024 |
Bruker Completes Acquisition of Molecular Diagnostics Innovator Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech • ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology • ELITech offers the proprietary, fully automated sample-to-answer (S2A) systems InGenius® and BeGenius® for molecular testing in mid-sized hospitals • Di |
|
| April 22, 2024 |
Exhibit 99.1 Bruker to Acquire the NanoString Business in an Asset Deal NanoString is an Established Leader and Valuable Innovator in Gene Expression Profiling and Spatial Transcriptomics for Scientific and Clinical Research in Healthcare BILLERICA, Massachusetts – April 22, 2024: Bruker Corporation (Nasdaq: BRKR) today announced that it has entered into a definitive acquisition agreement with Nan |
|
| April 22, 2024 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT by and between NanoString Technologies, Inc., and Bruker Corporation Dated as of April 17, 2024 TABLE OF CONTENTS Page Article 1 DEFINITIONS 2 1.1 Certain Defined Terms 2 1.2 Construction 17 Article 2 SALE AND PURCHASE OF ASSETS; LIABILITIES 18 2.1 Sale of Purchased Assets 18 2.2 Liabilities 20 2.3 Consideration 21 2.4 Closing 22 2.5 No Offset 22 2.6 Deposit 22 |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of incorporation) Commission File N |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 2, 2024 |
Seven-Year Term Loan Agreement dated as of March 29, 2024. EXHIBIT 10.2 Execution Version Published Deal CUSIP: 11679RAQ0 Published Facility CUSIP: 11679RAR8 TERM LOAN AGREEMENT dated as of March 29, 2024 among BRUKER CORPORATION, as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, and 11853195 The Lenders Party Hereto BofA SECURITIES, INC., as Sole Bookrunner and Arranger TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01 Defined Te |
|
| April 2, 2024 |
Three- and Five-Year Term Loan Agreement dated as of March 29, 2024. EXHIBIT 10.1 Execution Version Published Deal CUSIP: 11679RAM9 Published Three-Year Facility CUSIP: 11679RAP2 Published Five-Year Facility CUSIP: 11679RAN7 TERM LOAN AGREEMENT dated as of March 29, 2024 among BRUKER CORPORATION, as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, and 11828767 The Lenders Party Hereto JPMORGAN CHASE BANK, N.A., TD BANK, N.A., and WELLS FARGO BANK, N.A. |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 02, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer inc |
|
| February 29, 2024 |
EXHIBIT 21.1 SUBSIDIARIES OF BRUKER CORPORATION Name of Subsidiary Jurisdiction of Incorporation Acquifer Imaging GmbH (46) Germany Acuity Spatial Genomics, Inc. (33) Delaware, U.S.A. Agapetus GmbH (23) Austria Alicona Imaging GmbH (24) Austria Anasys Instruments Corporation (8) California, U.S.A. Bruker Norway AS (21) Norway Biognosys, AG (43) Switzerland Biognosys, Inc. (44) Delaware, U.S.A. Bru |
|
| February 29, 2024 |
Bruker Corporation Compensation Recoupment Policy EXHIBIT 97.1 BRUKER CORPORATION COMPENSATION RECOUPMENT POLICY 1. Purpose Bruker Corporation (“Bruker” or the “Company”) has adopted this Compensation Recoupment Policy (“Policy”) to implement the mandatory recoupment or “clawback” of compensation in the event of a Restatement in compliance with the applicable rules of the Nasdaq Stock Market (“Nasdaq”). Capitalized terms used, but not immediately |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION (Exact |
|
| February 29, 2024 |
EXHIBIT 10.29 From: Bruker Invest AG, a stock company, organized under the laws of Switzerland, having its registered office at Industriestrasse 26, Fallenden, CH-8117, Switzerland and registered with the Commercial register of canton Zurich under the number CHE-100.756.943 (the “Promisor”); To: Tecfin S.à r.l., a private limited liability company (société à responsabilité limitée) organized under |
|
| February 29, 2024 |
EXHIBIT 10.31 WARRANTY AGREEMENT BY AND BETWEEN BRUKER INVEST AG TECFIN S.À R.L. MR. CHRISTOPH GAUER ELIMAN AND ELIMAN 2 WITH RESPECT TO TECINVEST S.À R.L. TECBID S.À R.L. ELITECH MEPCO SAS ELITECH GROUP SAS AND TECBID US, INC. AND ALL THEIR DIRECT AND INDIRECT SUBSIDIARIES Dated: February 27, 2024 TABLE OF CONTENTS Page Article I INTERPRETATION 3 1.1 Certain Definitions. 3 1.2 Additional Definiti |
|
| February 29, 2024 |
EXHIBIT 10.30 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN Bruker Invest AG, on the one hand, AND THE SELLERS IDENTIFIED HEREIN, on the other hand, WITH RESPECT TO TECINVEST S.À R.L. ELIMAN S.A.S. ELIMAN 2 S.A.S. Dated: February 27, 2024 - ii - 127615582 TABLE OF CONTENTS Article Page Article 1 INTERPRETATION 3 1.1 Certain Definitions. 3 1.2 Additional Definitions. 11 1.3 Principles of Interpretat |
|
| February 13, 2024 |
BRKR / Bruker Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Bruker Corp Title of Class of Securities: Common Stock CUSIP Number: 116794108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| February 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer |
|
| February 13, 2024 |
Bruker Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Bruker Reports Fourth Quarter and Full Year 2023 Financial Results • Q4 2023 revenues of $854.5 million, up 20.6% year-over-year (yoy); organic revenue up 15.9% yoy • Q4 2023 GAAP EPS of $1.41, including a $0.99 per share gain on PhenomeX acquisition[1]; • Q4 2023 non-GAAP EPS of $0.70, down 5.4% yoy; pro forma non-GAAP EPS excluding PhenomeX acquisition up 8.1% yoy • Full year 2023 r |
|
| February 12, 2024 |
Note Purchase Agreement dated as of February 8, 2024 Execution Version Bruker Corporation CHF 50,000,000 2.60% Series A Senior Notes due April 15, 2036 and CHF 50,000,000 2.62% Series B Senior Notes due April 15, 2039 Note Purchase Agreement Dated February 8, 2024 FILENAME Note Purchase Agreement (2024-B) 4858-3466-9986 v5.docx 4427787 Table of Contents Section Heading Page Section 1.1. Authorization of Notes 1 Section 1.2. Incremental Leverage Fee |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* BRUKER CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 116794108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 02, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer |
|
| February 2, 2024 |
Note Purchase Agreement dated as of February 1, 2024. Execution Version Bruker Corporation CHF 50,000,000 2.56% Series A Senior Notes due April 15, 2034 CHF 146,000,000 2.62% Series B Senior Notes due April 15, 2036 And CHF 135,000,000 2.71% Series C Senior Notes due April 15, 2039 Note Purchase Agreement Dated February 1, 2024 FILENAME Note Purchase Agreement 4863-9295-9893 v18.docx 4426706 Table of Contents Section Heading Page Section 1.1. Authori |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer i |
|
| January 19, 2024 |
Execution Version Published Deal CUSIP: 11679RAK3 Published Facility CUSIP: 11679RAL1 AMENDED AND RESTATED CREDIT AGREEMENT dated as of January 18, 2024 among BRUKER CORPORATION, BRUKER INVEST AG, and BRUKER FINANCE B. |
|
| January 8, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Emp |
|
| December 26, 2023 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 c For the transition period from to Commission File Number 000-30833 |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer i |
|
| November 2, 2023 |
Bruker Reports Third Quarter 2023 Financial Results Exhibit 99.1 Bruker Reports Third Quarter 2023 Financial Results • Q3 2023 revenues of $742.8 million, up 16.3% year-over-year (yoy); organic revenue up 10.9% yoy • Q3 2023 GAAP EPS $0.60; non-GAAP EPS $0.74, up 12.1% yoy • Bruker increases FY 2023 revenue guidance to $2.88-$2.91 billion; implies reported revenue growth of 14%-15% yoy, and organic revenue growth of 11.5%-12.5% yoy, with organic gr |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) PHENOMEX INC. (Name of Subject Company (issuer)) BIRD MERGERSUB CORPORATION (Offeror) a wholly owned subsidiary of BRUKER CORPORATION (Parent of Offeror) (Names of Filing Persons (identifying status as |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) PHENOMEX INC. (Name of Subject Company (issuer)) BIRD MERGERSUB CORPORATION (Offeror) a wholly owned subsidiary of BRUKER CORPORATION (Parent of Offeror) (Names of Filing Persons (identifying status as |
|
| August 31, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO PHENOMEX INC. |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHENOMEX INC. (Name of Subject Company (issuer)) BIRD MERGERSUB CORPORATION (Offeror) a wholly owned subsidiary of BRUKER CORPORATION (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issuer o |
|
| August 31, 2023 |
Confidentiality Agreement, dated as of July 11, 2023, between PhenomeX, Inc. and Bruker Corporation. EX-99.(d)(3) Exhibit (d)(3) Confidentiality Agreement July 11, 2023 Bruker Corporation 40 Manning Road Billerica, MA 01821 Re: Confidentiality Agreement Ladies and Gentlemen: In connection with the consideration by Bruker Corporation (“you”) of a possible transaction involving PhenomeX, Inc. (the “Company” and, together with you, collectively, the “parties” and each individually, a “party”), the C |
|
| August 31, 2023 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of PHENOMEX INC. at $1.00 per share, net in cash, without interest Pursuant to the Offer to Purchase dated August 31, 2023 by BIRD MERGERSUB CORPORATION a wholly-owned subsidiary of BRUKER CORPORATION THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., NEW YORK CITY TIME ON SEPTEMBER 2 |
|
| August 31, 2023 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). Exhibit (a) (1) (B) Letter of Transmittal to Tender Shares of Common Stock of PHENOMEX INC. |
|
| August 31, 2023 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of PHENOMEX INC. at $1.00 per share, net in cash, without interest Pursuant to the Offer to Purchase dated August 31, 2023 by BIRD MERGERSUB CORPORATION a wholly-owned subsidiary of BRUKER CORPORATION THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., NEW YORK CITY TIME, ON SEPTEMBER |
|
| August 31, 2023 |
Summary Advertisement, as published in The Wall Street Journal on August 31, 2023 EX-99.(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is being made only by the Offer to Purchase, dated August 31, 2023 (the “Offer to Purchase”) and the related Letter of Transmittal (the “Letter of Transmittal”), as each may be amended or supplemented from time to time, a |
|
| August 31, 2023 |
Offer to Purchase, dated August 31, 2023. EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of PHENOMEX INC. at $1.00 per share, net in cash, without interest, by BIRD MERGERSUB CORPORATION a wholly owned subsidiary of BRUKER CORPORATION THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., NEW YORK CITY TIME, ON SEPTEMBER 28, 2023, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMI |
|
| August 17, 2023 |
Joint Press Release issued on August 17, 2023. EX-99.1 Exhibit 99.1 Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction Acquisition initiates Bruker’s entry into functional single-cell biology research solutions BILLERICA, Massachusetts and EMERYVILLE, California, August 17, 2023 — Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they h |
|
| August 17, 2023 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHENOMEX INC. (Name of Subject Company (issuer)) BIRD MERGERSUB CORPORATION (Offeror) a wholly owned subsidiary of BRUKER CORPORATION (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer inc |
|
| August 3, 2023 |
Bruker Reports Second Quarter 2023 Financial Results Exhibit 99.1 Bruker Reports Second Quarter 2023 Financial Results • Q2 2023 revenues of $681.9 million, up 15.9% year-over-year (yoy); organic revenue up 13.5% yoy • Q2 2023 GAAP EPS $0.39; non-GAAP EPS $0.50, up 11.1% yoy • Bruker increases FY 2023 revenue guidance to $2.85-$2.90 billion; implies revenue growth of 12.5%-14.5%, and organic revenue growth at 9.5%-11.5% BILLERICA, Massachusetts – Au |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Employ |
|
| June 2, 2023 |
As filed with the Securities and Exchange Commission on June 2, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 2, 2023 Registration No. |
|
| June 2, 2023 |
EX-4.3 Table of Contents Exhibit 4.3 BRUKER CORPORATION TO [NAME OF TRUSTEE] Trustee Indenture Dated as of , 20 Subordinated Debt Securities Table of Contents TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101 Definitions 2 SECTION 102 Compliance Certificates and Opinions 11 SECTION 103 Form of Documents Delivered to Trustee 12 SECTION 104 Acts o |
|
| June 2, 2023 |
EX-FILING FEES 6 d489562dexfilingfees.htm EX-FILING FEES Table of Contents Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bruker Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Uni |
|
| June 2, 2023 |
EX-4.2 Table of Contents Exhibit 4.2 BRUKER CORPORATION TO [NAME OF TRUSTEE] Trustee Indenture Dated as of , 20 Senior Debt Securities Table of Contents TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 101. Definitions 1 SECTION 102. Compliance Certificates and Opinions 9 SECTION 103. Form of Documents Delivered to Trustee 10 SECTION 104. Acts of |
|
| May 26, 2023 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report BRUKER CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-30833 04-3110160 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 40 Manning Road, Billerica, MA 01821 (Address of principal executive office |
|
| May 26, 2023 |
EX-1.01 2 brkr-ex101.htm EX-1.01 Exhibit 1.01 Bruker Corporation Conflict Minerals Report For the Reporting Period from January 1, 2022 to December 31, 2022 Introduction This Conflict Minerals Report (“Report”) of Bruker Corporation and its consolidated subsidiaries for the reporting period from January 1, 2022, to December 31, 2022 (“Reporting Period”) has been prepared pursuant to Rule 13p-1 (th |
|
| May 15, 2023 |
Exhibit 99.1 Bruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board Declares Quarterly Dividend BILLERICA, Massachusetts – May 15, 2023 – Bruker Corporation (Nasdaq: BRKR) today announced that on May 12, 2023, its Board of Directors approved a new share repurchase authorization for the purchase of up to $500 million of the Company’s common stock over a two-year p |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer incor |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer incorp |
|
| May 4, 2023 |
Bruker Reports First Quarter 2023 Financial Results Exhibit 99.1 Bruker Reports First Quarter 2023 Financial Results • Q1 2023 revenues of $685.3 million, up 15.2% year-over-year (yoy); organic revenue up 17.6% yoy • Q1 2023 GAAP EPS $0.52; non-GAAP EPS $0.64, up 30.6% yoy • Bruker increases FY 2023 guidance for revenue to $2.83-$2.88 billion and for non-GAAP EPS to $2.55-$2.60; implies revenue growth to 12%-14%, and organic revenue growth of 9%-11 |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION (Exact |
|
| March 1, 2023 |
EXHIBIT 21.1 SUBSIDIARIES OF BRUKER CORPORATION Name of Subsidiary Jurisdiction of Incorporation Acuity Spatial Genomics, Inc. (33) Delaware, U.S.A. Advanced Diagnostic Solutions (Pty) Ltd. (31) South Africa Agapetus GmbH (23) Austria Alicona Imaging GmbH (24) Austria Anasys Instruments Corporation (8) California, U.S.A. Biocetra AS (21) Norway Bruker (Beijing) Scientific Technology Co., Ltd. (11) |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. E |
|
| February 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of (Commission (I.R.S. Employer i |
|
| February 9, 2023 |
BRKR / Bruker Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Bruker Corp. Title of Class of Securities: Common Stock CUSIP Number: 116794108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| February 9, 2023 |
Bruker Reports Fourth Quarter and Fiscal Year 2022 Financial Results Exhibit 99.1 Bruker Reports Fourth Quarter and Fiscal Year 2022 Financial Results • Q4 2022 revenues $708.4 million, up 3.6% year-over-year (yoy); organic revenue growth of 8.9% • Q4 2022 GAAP EPS $0.66; non-GAAP EPS $0.74, up 25.4% yoy • FY 2022 revenues $2.531 billion, up 4.7% yoy; organic revenue growth of 10.2% • FY 2022 GAAP EPS $1.99; non-GAAP EPS $2.34, up 11.4% yoy • Bruker expects FY 2023 |
|
| February 8, 2023 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BRUKER CORP (Name of Issuer) Common Stock (Title of Class of Securities) 116794108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 23, 2023 |
BRKR / Bruker Corporation / LAUKIEN JOERG C - SC 13G Passive Investment SC 13G 1 tm233932d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Bruker Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 116794108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 9, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Emp |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION ( |
|
| November 4, 2022 |
EXHIBIT 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?) dated as of September 30, 2022, by and among BRUKER CORPORATION, a Delaware corporation (the ?Company?), the Subsidiaries (if any) of the Company party to the Credit Agreement as borrowers (each a ?Designated Borrower? and, together with the Company, the ?Borrowers? and, each a ?Borrower? |
|
| November 4, 2022 |
EXHIBIT 10.2 SECOND AMENDMENT TO TERM LOAN AGREEMENT This SECOND AMENDMENT TO TERM LOAN AGREEMENT (this ?Amendment?) dated as of September 30, 2022, by and among BRUKER CORPORATION, a Delaware corporation (the ?Company?), the Subsidiaries (if any) of the Company party to the Term Loan Agreement as borrowers (each a ?Designated Borrower? and, together with the Company, the ?Borrowers? and, each a ? |
|
| November 3, 2022 |
Bruker Reports Third Quarter 2022 Financial Results Exhibit 99.1 Bruker Reports Third Quarter 2022 Financial Results ? Q3 2022 reported revenue growth of 4.9% year-over-year (yoy); organic revenue growth of 12.7% ? Q3 2022 GAAP operating margin 20.6%; non-GAAP operating margin 22.4%, up 180 basis points yoy ? Q3 2022 GAAP EPS $0.59; non-GAAP EPS $0.66, up 4.8% yoy ? Given strong year-to-date performance and high backlog, Bruker is raising its FY 20 |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Em |
|
| August 5, 2022 | ||
| August 5, 2022 |
EXHIBIT 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this ?Agreement?) dated as of June 16, 2022, by and among BRUKER CORPORATION, a Delaware corporation (the ?Company?), the Subsidiaries (if any) of the Company party to the Credit Agreement as borrowers (each a ?Designated Borrower? and, together with the Company, the ?Borrowers? and, each a ?Borrower?), the |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION (Exact |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Empl |
|
| August 3, 2022 |
Bruker Reports Second Quarter 2022 Financial Results Exhibit 99.1 Bruker Reports Second Quarter 2022 Financial Results ? Q2 2022 reported revenue growth of 3.1% year-over-year (yoy); organic revenue growth of 8.8% ? Q2 2022 GAAP EPS $0.33; non-GAAP EPS $0.45, up 2.3% yoy ? Maintaining FY 2022 guidance for high, single-digit organic revenue growth, non-GAAP operating profit margin expansion and non-GAAP EPS increase BILLERICA, Massachusetts ? August |
|
| June 3, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 3, 2022 |
Bruker Corporation Employee Stock Purchase Plan Exhibit 99.1 BRUKER CORPORATION EMPLOYEE STOCK PURCHASE PLAN (Effective July 1, 2022) I. PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of Bruker Corporation (the ?Company?) by providing eligible employees with the opportunity to acquire a proprietary interest in the Company through participation in a payroll-deduction based employee stock purchase plan |
|
| June 3, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Bruker Corporation (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| June 1, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) Com |
|
| May 25, 2022 |
EX-1.01 2 brkr-ex101.htm EX-1.01 Exhibit 1.01 Bruker Corporation Conflict Minerals Report For the Reporting Period from January 1, 2021 to December 31, 2021 Introduction This Conflict Minerals Report (“Report”) of Bruker Corporation and its consolidated subsidiaries for the reporting period from January 1, 2021 to December 31, 2021 (“Reporting Period”) has been prepared pursuant to Rule 13p-1 (the |
|
| May 25, 2022 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report BRUKER CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-30833 04-3110160 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 40 Manning Road, Billerica, MA 01821 (Address of principal executive office |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION (Exac |
|
| May 4, 2022 |
Bruker Reports First Quarter Financial Results Exhibit 99.1 Bruker Reports First Quarter Financial Results ? Q1 2022 revenue growth of 7.3% year-over-year (yoy); organic revenue growth of 10.5% ? Q1 2022 GAAP EPS $0.41; non-GAAP EPS $0.49, up 11.4% yoy ? Raising fiscal year 2022 organic revenue outlook on strong demand for the Company?s high-performance life science tools, scientific instruments and diagnostic solutions BILLERICA, Massachusett |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Employe |
|
| April 22, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) C |
|
| March 16, 2022 |
Bruker Appoints Philip Ma to its Board of Directors Exhibit 99.1 Bruker Appoints Philip Ma to its Board of Directors BILLERICA, Massachusetts, March 16, 2022 (BUSINESS WIRE) ? Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. Dr. Philip Ma is Chief Executive Officer, President, and Founder of PrognomiQ Dr. Ma is Chief Executive Officer, |
|
| February 28, 2022 |
Bruker Corporation 2022 Short-Term Incentive Compensation Program Exhibit 10.15 Bruker Corporation 2022 Short-Term Incentive Compensation Program Program Objectives The Bruker Corporation (?Bruker? or the ?Company?) 2022 Short-Term Incentive Compensation Program (the ?ICP? or ?Program?) is designed to reward employees for performance that contributes to the Company?s growth and financial success. The Program is designed to reward several layers of success at the |
|
| February 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant |
|
| February 28, 2022 |
EXHIBIT 21.1 SUBSIDIARIES OF BRUKER CORPORATION Name of Subsidiary Jurisdiction of Incorporation Acuity Spatial Genomics, Inc. (35) Delaware, U.S.A. Advanced Diagnostic Solutions (Pty) Ltd. (33) South Africa Agapetus GmbH (25) Austria Alicona Imaging GmbH (26) Austria Anasys Instruments Corporation (9) California, U.S.A. Biocetra AS (23) Norway Bruker Arabia Limited (25) Saudi Arabia Bruker AXS Ho |
|
| February 11, 2022 |
Bruker Reports Fourth Quarter and Fiscal Year 2021 Financial Results Exhibit 99.1 Bruker Reports Fourth Quarter and Fiscal Year 2021 Financial Results ? Q4 2021 revenues $683.5M, up 8.9% year-over-year (yoy); organic revenue growth of 11.4% yoy ? Q4 2021 GAAP EPS $0.50; non-GAAP EPS $0.59, up $0.01 yoy ? FY 2021 revenues of $2.42B, up 21.7% yoy; organic revenue growth of 19.1% yoy ? FY 2021 GAAP EPS $1.81; non-GAAP EPS $2.10, up 55.6% yoy ? Solid organic revenue an |
|
| February 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization |
|
| February 9, 2022 |
BRKR / Bruker Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Bruker Corp. Title of Class of Securities: Common Stock CUSIP Number: 116794108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| January 24, 2022 |
BRKR / Bruker Corporation / LAUKIEN JOERG C - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 23) * Bruker Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 116794108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 10, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) |
|
| December 8, 2021 |
Note Purchase Agreement dated as of December 7, 2021 Exhibit 10.1 EXECUTION VERSION BRUKER CORPORATION CHF 300,000,000 0.88% Series A Senior Notes due December 8, 2031 AND ?150,000,000 1.03% Series B Senior Notes due December 8, 2031 NOTE PURCHASE AGREEMENT Dated December 7, 2021 TABLE OF CONTENTS SECTION HEADING PAGE Section 1.1. Authorization of Notes 1 Section 1.2. Incremental Leverage Fee 1 Section 1.3. Recalculation of Interest 2 SECTION 2. SAL |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) |
|
| November 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BR |
|
| November 1, 2021 |
Bruker Reports Third Quarter 2021 Financial Results Exhibit 99.1 Bruker Reports Third Quarter 2021 Financial Results ? Q3 2021 revenues of $608.9 million, up 19.1% year-over-year (yoy); organic growth of 17.8% ? Q3 2021 GAAP EPS of $0.57, up 63% yoy; non-GAAP EPS of $0.63, up 50% yoy ? Raising FY 2021 guidance significantly on strong demand for Bruker?s products and solutions BILLERICA, Massachusetts ? November 1, 2021 ? Bruker Corporation (Nasdaq: |
|
| November 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) |
|
| August 5, 2021 |
First Amendment to Term Loan Agreement, dated as of May 12, 2021 Exhibit 10.1 Execution Version FIRST AMENDMENT TO TERM LOAN AGREEMENT This FIRST AMENDMENT TO TERM LOAN AGREEMENT (this ?Agreement?) dated as of May 12, 2021, by and among BRUKER CORPORATION, a Delaware corporation (the ?Company?), the Subsidiaries (if any) of the Company party to the Term Loan Agreement as borrowers (each a ?Designated Borrower? and, together with the Company, the ?Borrowers? and |
|
| August 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER |
|
| August 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) C |
|
| August 2, 2021 |
Bruker Reports Second Quarter 2021 Financial Results Exhibit 99.1 Bruker Reports Second Quarter 2021 Financial Results ? Q2 2021 revenue growth of 34.4% year-over-year; organic revenue growth of 27.2% ? Q2 2021 GAAP EPS of $0.38; non-GAAP EPS of $0.44, compared to $0.21 in Q2 2020 ? Strong financial performance in the Bruker Scientific Instruments and BEST businesses drives a further increase in fiscal year 2021 guidance BILLERICA, Massachusetts ? A |
|
| June 17, 2021 |
Bruker Updates FY 2021 Guidance and Provides Medium Term Outlook at Virtual Investor Day Exhibit 99.1 Bruker Updates FY 2021 Guidance and Provides Medium Term Outlook at Virtual Investor Day BILLERICA, Mass. ? June 17, 2021 ? At its 2021 Virtual Investor Day today, Bruker Corporation (Nasdaq: BRKR) will discuss the Company?s strategy and Project Accelerate 2.0 initiatives, including the Company?s potential high-growth opportunities in the areas of proteomics and spatial biology. Bruke |
|
| June 17, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) Co |
|
| June 7, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) Com |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) Com |
|
| June 1, 2021 |
EX-1.01 2 d179540dex101.htm EX-1.01 Exhibit 1.01 Bruker Corporation Conflict Minerals Report For the Reporting Period from January 1, 2020 to December 31, 2020 Introduction This Conflict Minerals Report (“Report”) of Bruker Corporation and its consolidated subsidiaries for the reporting period from January 1, 2020 to December 31, 2020 (“Reporting Period”) has been prepared pursuant to Rule 13p-1 ( |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report BRUKER CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-30833 04-3110160 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 40 Manning Road, Billerica, MA 01821 (Address of principal executive offices) |
|
| May 13, 2021 |
Exhibit 99.1 Bruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board also Declares Quarterly Dividend BILLERICA, Mass. ? May 13, 2021 ? Bruker Corporation (Nasdaq: BRKR) today announced that on May 12, 2021, its Board of Directors approved a new share repurchase authorization for the purchase of up to $500 million of the Company?s common stock over a two-year peri |
|
| May 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) Com |
|
| May 10, 2021 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) Comm |
|
| May 5, 2021 |
Bruker Reports First Quarter 2021 Financial Results Exhibit 99.1 Bruker Reports First Quarter 2021 Financial Results ? Q1 2021 revenue growth of 30.8% year-over-year, organic revenue growth of 23.8% ? Q1 2021 GAAP EPS of $0.37; non-GAAP EPS of $0.44, compared to $0.14 in Q1 2020 ? Raising fiscal year 2021 outlook on strong demand for the Company?s high-performance life science tools, scientific instruments and diagnostic solutions BILLERICA, Massac |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 20, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 13, 2021 |
Bruker Announces First Quarter 2021 Preliminary Revenue EX-99.1 Exhibit 99.1 Bruker Announces First Quarter 2021 Preliminary Revenue BILLERICA, Massachusetts – April 13, 2021 – Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2021 in a range of $549-$554 million, representing reported revenue growth of approximately 30% to 31%, compared to the first quarter of 2020. Adjusting for the impact of |
|
| April 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Incorporation or organization) C |
|
| March 1, 2021 |
EXHIBIT 21.1 ? SUBSIDIARIES OF BRUKER CORPORATION ? ? Name of Subsidiary Jurisdiction of Incorporation ? Applied Diagnostic Solutions (Pty) Ltd. (34) ? South Africa ? Agapetus GmbH (25) ? Austria ? Alicona Imaging GmbH (26) ? Austria ? Anasys Instruments Corporation (9) ? California, U.S.A. ? Biocetra AS (23) ? Norway ? Bruker Advanced Supercon GmbH (2) ? Germany ? Bruker Arabia Limited (25) ? Sau |
|
| March 1, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. E |
|
| February 16, 2021 |
Bruker Reports Fourth Quarter and Fiscal Year 2020 Financial Results Exhibit 99.1 Bruker Reports Fourth Quarter and Fiscal Year 2020 Financial Results ? Q4 2020 revenues up 4.6% year-over-year; organic revenue declines 0.4% ? Q4 2020 GAAP EPS of $0.45; non-GAAP EPS of $0.58 ? Expanded Project Accelerate 2.0 in proteomics, spatial biology and molecular diagnostics ? Strong revenue growth, Non-GAAP margin expansion and EPS growth expected in FY 2021 BILLERICA, Massac |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Bruker Corp. Title of Class of Securities: Common Stock CUSIP Number: 116794108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 22) * Bruker Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 116794108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 11, 2021 |
Regulation FD Disclosure, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Em |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BR |
|
| November 2, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Em |
|
| November 2, 2020 |
Bruker Reports Third Quarter 2020 Financial Results Exhibit 99.1 Bruker Reports Third Quarter 2020 Financial Results · Q3 2020 revenues of $511.4 million decline 1.9% year-over-year; organic revenue down 4.6% · Q3 2020 GAAP EPS of $0.35, compared to $0.39 in Q3 2019; non-GAAP EPS of $0.42, compared to $0.43 in Q3 2019 · Significant sequential improvements compared to Q2 2020 results BILLERICA, Massachusetts – November 2, 2020 – Bruker Corporation ( |
|
| September 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. E |
|
| September 8, 2020 |
Bruker Appoints Bonnie H. Anderson to its Board of Directors Exhibit 99.1 Bruker Appoints Bonnie H. Anderson to its Board of Directors BILLERICA, Massachusetts – September 8, 2020 – Bruker Corporation (Nasdaq: BRKR) today announced that it has appointed Bonnie H. Anderson to serve on its board of directors, effective as of September 3, 2020. Ms. Anderson is Co-Founder, Chairman of the Board and CEO of Veracyte, a global genomic diagnostics company that impr |
|
| August 7, 2020 |
First Amendment to the Note Purchase Agreement, date January 18, 2012 Exhibit 10.1 EXECUTION VERSION BRUKER CORPORATION FIRST AMENDMENT Dated as of April 17, 2020 to the NOTE PURCHASE AGREEMENT Dated as of January 18, 2012 RE: $105,000,000 4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022 $100,000,000 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024 FIRST AMENDMENT TO THE NOTE PURCHASE AGREEMENT THIS FIRST AMENDMENT dated as of April 1 |
|
| August 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER |
|
| August 7, 2020 |
Amended and Restated Bylaws of Bruker Corporation Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF BRUKER CORPORATION (A Delaware Corporation) TABLE OF CONTENTS Page ARTICLE 1 CERTIFICATE OF INCORPORATION 1 Section 1.1 Contents 1 Section 1.2 Certificate in Effect 1 ARTICLE 2 MEETINGS OF STOCKHOLDERS 1 Section 2.1 Place 1 Section 2.2 Annual Meeting 1 Section 2.3 Notice of Stockholder Business 1 Section 2.4 Special Meetings 13 Section 2.5 Notice of Meet |
|
| August 7, 2020 |
First Amendment to the Note Purchase Agreement, dated as of December 11, 2019 EX-10.2 4 brkr-20200630xex10d2.htm EXHIBIT-10.2 Exhibit 10.2 EXECUTION VERSION BRUKER CORPORATION FIRST AMENDMENT Dated as of April 17, 2020 to the NOTE PURCHASE AGREEMENT Dated as of December 11, 2019 RE: CHF 297,000,000 1.01% Senior Notes, due December 11, 2029 FIRST AMENDMENT TO THE NOTE PURCHASE AGREEMENT THIS FIRST AMENDMENT dated as of April 17, 2020 and effective as of March 25, 2020 (the o |
|
| August 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Empl |
|
| August 3, 2020 |
Bruker Reports Second Quarter 2020 Financial Results EX-99.1 2 tm2026412d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bruker Reports Second Quarter 2020 Financial Results · COVID-19 disruption and softer demand negatively affect Q2 2020 financial results · Q2 2020 revenue decline of 13.4% year-over-year; organic revenue decline of 12.7% · Q2 2020 GAAP EPS of $0.16, compared to $0.23 in Q2 2019; non-GAAP EPS of $0.21, compared to $0.33 in Q2 2019 BILLERICA, |
|
| July 22, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Emplo |
|
| May 29, 2020 |
Conflict Minerals Report of Bruker Corporation. Exhibit 1.01 Bruker Corporation Conflict Minerals Report For the Year Ended December 31, 2019 Introduction This Conflict Minerals Report (“Report”) of Bruker Corporation and its consolidated subsidiaries for the year ended December 31, 2019 has been prepared pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended. The Rule requires disclosure of certai |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report BRUKER CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-30833 04-3110160 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 40 Manning Road, Billerica, MA 01821 (Address of principal executive offices) |
|
| May 26, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Employ |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER |
|
| May 6, 2020 |
Bruker Reports First Quarter 2020 Financial Results Exhibit 99.1 Bruker Reports First Quarter 2020 Financial Results • Q1 2020 revenue decline of 8.1% year-over-year, organic revenue decline of 7.9% • Q1 2020 GAAP EPS of $0.07, compared to $0.20 in Q1 2019; non-GAAP EPS of $0.14, compared to $0.28 in Q1 2019 • COVID-19 disruption expected to negatively affect Q2 2020 financial results BILLERICA, Massachusetts – May 6, 2020 – Bruker Corporation (Nas |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Employe |
|
| April 22, 2020 |
BRKR / Bruker Corp. DEF 14A - - DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Empl |
|
| March 27, 2020 |
EXHIBIT 21.1 SUBSIDIARIES OF BRUKER CORPORATION Name of Subsidiary Jurisdiction of Incorporation Bruker Energy & Supercon Technologies, Inc. Delaware, U.S.A. Bruker HTS GmbH (1) Germany Bruker Advanced Supercon GmbH (2) Germany Bruker EAS GmbH (2) Germany Hydrostatic Extrusions Ltd. (1) United Kingdom RI Research Instruments GmbH (3) Germany Bruker AXS LLC (9) Delaware, U.S.A. Bruker AXS GmbH (4) |
|
| March 27, 2020 |
Bruker Announces Final Fourth Quarter and Fiscal Year 2019 Financial Results Exhibit 99.1 Bruker Announces Final Fourth Quarter and Fiscal Year 2019 Financial Results · Q4 2019 revenue growth of 8.4%, organic revenue growth of 5.2% year-over-year · FY 2019 revenue growth of 9.3%, organic revenue growth of 5.7% year-over-year · Q4 2019 GAAP EPS of $0.44; non-GAAP EPS of $0.53, a decrease of 2% year-over-year · FY 2019 GAAP EPS of $1.26; non-GAAP EPS of $1.57, an increase of |
|
| March 27, 2020 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Bruker Corporation’s (“we,” “us,” and “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF CAPITAL STOCK The following descri |
|
| March 27, 2020 |
Restated Certificate of Incorporation of Bruker Corporation Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF BRUKER CORPORATION FIRST: The name of this corporation shall be: Bruker Corporation. SECOND: Its registered office in the State of Delaware is to be located at 251 Little Falls Drive, Wilmington, County of New Castle, 19808, and its registered agent at such address is: CORPORATION SERVICE COMPANY. THIRD: The purpose or purposes of the corporatio |
|
| March 27, 2020 |
Exhibit 10.27 Supplement to the Managing Director Employment Contract dated 28 June 2012 between Bruker Daltonik GmbH Fahrenheitstr. 4 28359 Bremen - hereinafter referred to as ‘Company’ - and Mr. Jürgen Srega Hohenkampsweg 24f 28355 Bremen Nachtrag zum Geschäftsführeranstellungs vertrag vom 28. Juni 2012 zwischen der Bruker Daltonik GmbH Fahrenheitstr. 4 28359 Bremen - im Folgenden „Gesellschaft“ |
|
| March 27, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant |
|
| March 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Emplo |
|
| March 5, 2020 |
Bruker Receives Notification from Nasdaq Related to Delayed Annual Report on Form 10-K Exhibit 99.1 Bruker Receives Notification from Nasdaq Related to Delayed Annual Report on Form 10-K BILLERICA, Massachusetts – March 5, 2020 – Bruker Corporation (Nasdaq: BRKR) today announced that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of Bruker’s delay in filing its Annual Report on Form 10-K for the |
|
| March 3, 2020 |
BRKR / Bruker Corp. NT 10-K - - NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-30833 CUSIP NUMBER: 116794108 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o T |
|
| February 18, 2020 |
Bruker Reports Preliminary Fourth Quarter and Fiscal Year 2019 Operating Results Exhibit 99.1 Bruker Reports Preliminary Fourth Quarter and Fiscal Year 2019 Operating Results • Q4 2019 revenue growth of 8.4% and organic revenue growth of 5.2% year-over-year • FY 2019 revenue growth of 9.3% and organic revenue growth of 5.7% • Q4 2019 GAAP operating income of $117.7 million, non-GAAP operating income of $132.5 million • FY 2019 GAAP operating income of $300.9 million, non-GAAP |
|
| February 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. E |
|
| February 12, 2020 |
BRKR / Bruker Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Bruker Corp Title of Class of Securities: Common Stock CUSIP Number: 116794108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| January 30, 2020 |
BRKR / Bruker Corp. / LAUKIEN JOERG C - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 21) * Bruker Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 116794108 (CUSIP |
|
| January 13, 2020 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of Commission File No. (I.R.S. Em |
|
| December 12, 2019 |
Exhibit 10.2 TERM LOAN AGREEMENT dated as of December 11, 2019 among BRUKER CORPORATION, as a Borrower, The Other Borrowers Party Hereto, BANK OF AMERICA, N.A., as Administrative Agent, and The Lenders Party Hereto TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01 Defined Terms 1 SECTION 1.02 Classification of Loans and Borrowings 24 SECTION 1.03 Terms Generally 24 SECTION 1.04 Accountin |
|
| December 12, 2019 |
Exhibit 10.1 Published Deal CUSIP: 11679RAH0 Published Facility CUSIP: 11679RAJ6 CREDIT AGREEMENT dated as of December 11, 2019 among BRUKER CORPORATION, BRUKER INVEST AG, and BRUKER FINANCE B.V., as Borrowers, The Other Borrowers From Time to Time Party Hereto, BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and Issuing Bank, and The Lenders Party Hereto DEUTSCHE BANK SECURITIES |
|
| December 12, 2019 |
Note Purchase Agreement dated as of December 11, 2019 EX-10.3 4 tm1924821d1ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 Execution Version Bruker Corporation CHF 297,000,000 1.01% Senior Notes due December 11, 2029 Note Purchase Agreement Dated December 11, 2019 Table of Contents Section Heading Page Section 1.1. Authorization of Notes 1 Section 1.2. Incremental Leverage Fee 1 Section 1.3. Recalculation of Interest 2 Section 2. Sale and Purchase of Notes; Gua |
|
| December 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2019 BRUKER CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-30833 04-3110160 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| November 4, 2019 |
EXHIBIT 10.1 PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (this “Agreement”) is made and entered into as of this 31st day of October, 2019 (the “Effective Date”) by and between, Dirk D. Laukien and Frank Laukien, Trustees of 44 Manning Road Realty Trust, u/d/t dated October 4, 1994 and recorded with the Middlesex North District Registry of Deeds in Book 7291, Page 333 (hereinafter |
|
| November 4, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BR |
|
| October 31, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No. |
|
| October 31, 2019 |
Bruker Reports Third Quarter 2019 Financial Results Exhibit 99.1 Bruker Reports Third Quarter 2019 Financial Results · Q3-19 revenue growth of 11.7% and organic revenue growth of 7.6% year-over-year · Q3-19 GAAP EPS of $0.39; Q3-19 non-GAAP EPS of $0.43, up 16.2% year-over-year · Increasing FY 2019 non-GAAP EPS outlook to $1.59 to $1.62 BILLERICA, Massachusetts – October 31, 2019 – Bruker Corporation (Nasdaq: BRKR) today announced financial results |
|
| August 9, 2019 |
Bruker Corporation 2016 Incentive Compensation Plan Form of Restricted Stock Agreement(1) Exhibit 10.3 BRUKER CORPORATION RESTRICTED STOCK UNIT AGREEMENT UNDER 2016 INCENTIVE COMPENSATION PLAN This Restricted Stock Unit Agreement is entered into [date] by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “Company”) and [Name] (the “Participant”). The Company and its subsidiaries are herein together referred to as |
|
| August 9, 2019 |
Bruker Corporation 2016 Incentive Compensation Plan Form of Incentive Stock Option Agreement Exhibit 10.1 BRUKER CORPORATION INCENTIVE STOCK OPTION AGREEMENT UNDER 2016 INCENTIVE COMPENSATION PLAN This Incentive Stock Option Agreement is entered into [date] by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “Company”) and [Name] (the “Participant”). The Company and its subsidiaries are herein together referred to a |
|
| August 9, 2019 |
Bruker Corporation 2016 Incentive Compensation Plan Form of Non-Qualified Stock Option Agreement EX-10.2 3 brkr-20190630ex102d2d419.htm EXHIBIT 10.2 Exhibit 10.2 BRUKER CORPORATION NON-QUALIFIED STOCK OPTION AGREEMENT UNDER 2016 INCENTIVE COMPENSATION PLAN This Non-Qualified Stock Option Agreement is entered into [date] by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “Company”) and [Name] (the “Participant”). The Co |
|
| August 9, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-30833 (Commission File Number) 04-3110160 (IRS Employer Identification No. |
|
| August 1, 2019 |
Bruker Reports Second Quarter 2019 Financial Results Exhibit 99.1 Bruker Reports Second Quarter 2019 Financial Results · Q2-19 revenue growth of 10.5% and organic revenue growth of 4.8% year-over-year · Q2-19 GAAP EPS of $0.23; Q2-19 non-GAAP EPS of $0.33, up 32% year-over-year · Confirms FY 2019 revenue growth, non-GAAP operating margin expansion and earnings outlook BILLERICA, Massachusetts — August 1, 2019 — Bruker Corporation (Nasdaq: BRKR) toda |
|
| May 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2019 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No. |
|
| May 31, 2019 |
Conflict Minerals Report of Bruker Corporation. Exhibit 1.01 Bruker Corporation Conflict Minerals Report For the Year Ended December 31, 2018 Introduction This Conflict Minerals Report (“Report”) of Bruker Corporation and its consolidated subsidiaries for the year ended December 31, 2018 has been prepared pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended. The Rule requires disclosure of certai |
|
| May 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report BRUKER CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 000-30833 04-3110160 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 40 Manning Road, Billerica, MA 01821 (Address of principal executive offices) |
|
| May 20, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2019 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-30833 (Commission File Number) 04-3110160 (IRS Employer Identification No. |
|
| May 10, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| May 10, 2019 |
Bruker Announces New $300 Million Share Repurchase Authorization and Quarterly Dividend EX-99.1 2 a19-97741ex99d1.htm EX-99.1 Exhibit 99.1 Bruker Announces New $300 Million Share Repurchase Authorization and Quarterly Dividend BILERICA, Mass. — May 10, 2019 — Bruker Corporation (NASDAQ: BRKR) today announced that on May 9, 2019, its Board of Directors approved a new share repurchase authorization for the purchase of up to $300 million of the Company’s common stock over a two-year per |
|
| May 8, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended March 31, 2019 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER |
|
| May 2, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2019 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-30833 04-3110160 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| May 2, 2019 |
Bruker Reports First Quarter 2019 Financial Results Exhibit 99.1 Bruker Reports First Quarter 2019 Financial Results · Q1 2019 revenue growth of 6.9% year-over-year (yoy), organic revenue growth of 5.5% yoy; · Q1 2019 GAAP EPS of $0.20; Q1 2019 non-GAAP EPS of $0.28, up 16.7% yoy; · Q1 2019 GAAP operating margin of 9.1%; Q1 2019 non-GAAP operating margin of 13.5%, up 125 basis points (bps) yoy; · Raising full year guidance for revenue growth and ea |
